Key Presentations at AAIC 2026<\/p>\n
New Clinical Evidence on Kisunla (donanemab-azbt)<\/p>\n
On July 15, a Developing Topics Session, Donanemab in Early Symptomatic Alzheimer’s Disease: Evidence to Address Clinical Questions, will present new insights from TRAILBLAZER-ALZ 6 and the TRAILBLAZER-ALZ 2 long-term extension. Findings include new data on safety through modified titration and corticosteroid pretreatment as well as long-term extension evidence on biomarkers and the potential durability of clinical benefit.<\/p>\n
Advancing Diagnostics<\/p>\n
Also on July 15, Samantha Burnham, Ph.D., senior research scientist, Eli Lilly and Company, will present data showing P-tau217 blood biomarker assays demonstrated strong rule-in performance comparable to amyloid PET for identifying Alzheimer’s disease pathology in cognitively unimpaired individuals. Though blood biomarker tests and amyloid PET agents are not currently indicated for use in cognitively unimpaired individuals, the results generate support for a potentially scalable, accessible alternative to specialized imaging in the future.<\/p>\n
Advancing Scientific Methodology<\/p>\n
On July 13, as the organizer of the Featured Research Session, Lars Raket, Ph.D., Eli Lilly and Company, will deliver an oral presentation on external controls versus internal extrapolation in the TRAILBLAZER-ALZ 2 long-term extension (Room N10). The analysis addresses a key methodological question in Alzheimer’s disease research: how long-term outcomes are measured and interpreted in clinical trials, reflecting Lilly’s commitment to the scientific rigor that underpins credible long-term evidence generation.<\/p>\n
A full list of abstracts appears below. Presentations will be available at www.lilly.com<\/a> following their scheduled release times.<\/p>\n Abstract Title<\/p>\n Presenter<\/p>\n Presentation Details (Date, Time, Kisunla (donanemab-azbt)<\/p>\n External Controls vs. Internal Lars Raket<\/p>\n Featured 7\/13\/2026<\/p>\n Room: N10<\/p>\n Session: 9-10:30 a.m.<\/p>\n Donanemab in Early Nick Fox,<\/p>\n Emel Serap Hong Wang,<\/p>\n Erin Doty<\/p>\n Developing 7\/15\/2026 <\/p>\n 9-10:30 a.m.<\/p>\n Interim Analysis of the Krista Schroeder<\/p>\n Poster<\/p>\n 7\/12\/2026<\/p>\n Poster #8953<\/p>\n 7:30 a.m.-4:15 p.m.<\/p>\n Exhibit Hall<\/p>\n Diagnostics<\/p>\n Blood Biomarker Assays Samantha Oral<\/p>\n 7\/15\/2026<\/p>\n Room: S11<\/p>\n Session: 8-8:45 a.m. Baseline amyloid and tau Ilke Tunali<\/p>\n Poster<\/p>\n 7\/15\/2026<\/p>\n Biomarkers: Neuroimaging, Exhibit Hall<\/p>\n Evaluation of Diffusion Ajay Kurani<\/p>\n Poster<\/p>\n 7\/13\/2026 Exhibit Hall<\/p>\n Data-Driven Feature Map Ian Kennedy<\/p>\n Poster<\/p>\n 7\/13\/2026<\/p>\n 7:30 a.m.-4:15 p.m.<\/p>\n Exhibit Hall<\/p>\n Regional tau PET Extent to Vikas Kotari<\/p>\n Poster<\/p>\n 7\/11\/2026 and 7\/14\/2026<\/p>\n Biomarkers: Neuroimaging, *Will also be presented at Cross-sectional evaluation of Diana Otero<\/p>\n Poster<\/p>\n 7\/13\/2026<\/p>\n Biomarkers: Neuroimaging,<\/p>\n 7:30 a.m.-4:15 p.m.<\/p>\n Exhibit Hall<\/p>\n Health Economics and Outcomes Research (HEOR)<\/p>\n Defining Meaningful Change Scott Andrews <\/p>\n \u00a0<\/p>\n Poster<\/p>\n 7\/13\/2026<\/p>\n 7:30 a.m.-4:15 p.m.<\/p>\n Exhibit Hall: Developing \u00a0<\/p>\n Quantification of Benefit- Nalin Payakachat<\/p>\n \u00a0<\/p>\n Poster<\/p>\n 7\/13\/2026<\/p>\n 7:30 a.m.-4:15 p.m.<\/p>\n Exhibit Hall: Developing Drivers of Increased Zachary Sheff<\/p>\n Poster<\/p>\n 7\/12\/2026 <\/p>\n Poster #441<\/p>\n 7:30 a.m.-4:15 p.m.<\/p>\n Exhibit Hall<\/p>\n Neurocognitive, Biomarker, Nalin Payakachat<\/p>\n Poster<\/p>\n 7\/14\/2026<\/p>\n Poster #9036<\/p>\n 7:30 a.m.-4:15 p.m.<\/p>\n Exhibit Hall<\/p>\n Incident institutionalization Zachary Sheff<\/p>\n Poster<\/p>\n 7\/12\/2026<\/p>\n Poster # 7262<\/p>\n 7:30 a.m.-4:15 p.m.<\/p>\n Exhibit Hall<\/p>\n Risk Algorithms to Predict Nalin Payakachat<\/p>\n Poster<\/p>\n 7\/12\/2026<\/p>\n Poster # 2141<\/p>\n 7:30 a.m.-4:15 p.m.<\/p>\n Exhibit Hall<\/p>\n Natural Language Processing Krista Schroeder<\/p>\n Poster<\/p>\n 7\/15\/2026<\/p>\n Poster # 8947<\/p>\n 7:30 a.m.-4:15 p.m.<\/p>\n Exhibit Hall<\/p>\n About Alzheimer’s Disease Nearly 4 in 5 Americans say they would want to know if they had Alzheimer’s disease before experiencing symptoms or before symptoms interfere with their daily activities.4 \u00a0<\/p>\n About\u00a0Kisunla\u00ae (donanemab-azbt) INDICATION AND SAFETY SUMMARY WITH WARNINGS Warnings –\u00a0Kisunla\u00a0can cause Amyloid-Related Imaging Abnormalities or “ARIA.” This is a common side effect that does not usually cause any symptoms, but serious symptoms can occur. ARIA can be fatal.\u00a0ARIA is\u00a0most commonly seen\u00a0as\u00a0temporary swelling in an area or areas of the brain that usually goes away over time. Some people may also have spots of bleeding on the surface of or in the\u00a0brain\u00a0and infrequently, larger areas of bleeding in the brain can occur. Although most people do not have symptoms, some people have: \u00a0<\/p>\n Headache Confusion Some people have a genetic risk factor (homozygous apolipoprotein E \u03b54 gene carriers) that may cause an increased risk for ARIA. Talk to your healthcare provider about testing to see if you have this risk factor.\u00a0<\/p>\n You may be at higher risk of developing bleeding in the brain if you take medicines to reduce blood clots from forming (antithrombotic medicines) while receiving\u00a0Kisunla. Talk to your healthcare provider to see if you are on any medicines that increase this risk.\u00a0<\/p>\n Your healthcare provider will do magnetic resonance imaging (MRI) brain scans before and during your treatment with Kisunla to check you for ARIA. You should carry information that you are receiving\u00a0Kisunla, which can cause ARIA, and that ARIA symptoms can look like stroke symptoms. Call your healthcare provider or go to the nearest hospital emergency room right away if you have any of the symptoms listed above.\u00a0<\/p>\n There are registries that collect information on treatments for Alzheimer’s disease. Your healthcare provider can help you become enrolled in these registries.<\/p>\n Warnings –\u00a0Kisunla\u00a0can cause serious allergic and infusion-related reactions. Do not receive\u00a0Kisunla\u00a0if you have serious allergic reactions to donanemab-azbt\u00a0or any of the ingredients in\u00a0Kisunla.\u00a0Symptoms may include swelling of the face, lips, mouth, or eyelids,\u00a0problems\u00a0breathing, hives, chills, irritation of skin, nausea, vomiting, sweating, headache, or chest pain.\u00a0You will be monitored for at least 30 minutes after you receive\u00a0Kisunla\u00a0for any reaction. Tell your healthcare provider right away if you have these symptoms or any reaction during or after a\u00a0Kisunla\u00a0infusion.<\/p>\n Other common side effects\u00a0<\/p>\n Tell your healthcare provider right away if you have any side effects. These are not\u00a0all of\u00a0the possible side effects of\u00a0Kisunla. You can report side effects at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/a>.\u00a0<\/p>\n Before you receive\u00a0Kisunla, tell your healthcare provider:\u00a0<\/p>\n About all medicines you take, including prescription and over-the-counter medicines, as well as vitamins and herbal supplements.\u00a0Especially tell\u00a0your healthcare provider if you have medicines to reduce blood clots from forming (antithrombotic medicines, including aspirin).\u00a0 How to receive\u00a0Kisunla Learn more \u00a0 This summary provides basic information about\u00a0Kisunla. It does not include all information known about this medicine. Read the information given to you about\u00a0Kisunla. This information does not take the place of talking with your healthcare provider. Be sure to talk to your healthcare provider about\u00a0Kisunla. Your healthcare provider is the best person to help you decide if\u00a0Kisunla\u00a0is right for you.<\/p>\n DN CON BS APP\u00a0<\/p>\n Kisunla\u00ae is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.\u00a0<\/p>\n Frequently Asked Questions<\/p>\n How accurate are blood tests for diagnosing Alzheimer’s disease? About Lilly Trademarks and Trade Names Cautionary Statement Regarding Forward-Looking Statements References\u00a0<\/p>\n Alzheimer’s Disease International. 2026 Dementia statistics. https:\/\/www.alzint.org\/about\/dementia-facts-figures\/dementia-statistics\/<\/a>. Accessed 24 June 2026.\u00a0 Refer to:\u00a0\u00a0\u00a0\u00a0\u00a0Gina Goodenough; [email\u00a0protected]<\/a> (Media) Correction:\u202fTwo new rows have been added to the abstracts table.\u00a0<\/p>\n SOURCE Eli Lilly and Company<\/p>\n
Type\/#<\/p>\n
Location, Session Time)<\/p>\n
Extrapolation in the
TRAILBLAZER-ALZ 2 Long-
Term Extension<\/p>\n
Research
Session <\/p>\n
Symptomatic Alzheimer’s
Disease: Evidence to
Address Clinical Questions<\/p>\n
Monkul Nery, <\/p>\n
Topics Session<\/p>\n
United Kingdom
Donanemab Controlled
Access Programme: Early
Patient Characteristics and
Prescribing Patterns <\/p>\n
Demonstrate Strong Rule-in
Performance for Identifying
Cognitively Unimpaired AD <\/p>\n
Burnham<\/p>\n
\u00a0<\/p>\n
PET characteristics in early
Alzheimer’s Disease: Results
from the TRAILRUNNER-ALZ
3 PET Addendum <\/p>\n
8 a.m.- 3 p.m.<\/p>\n
Tensor Imaging biomarkers
in phase 2 PROSPECT-ALZ
study of Ceperognastat in
early symptomatic
Alzheimer’s disease <\/p>\n
7:30 a.m.-4:15 p.m.<\/p>\n
Associating Baseline
Florbetapir-PET Uptake
Patterns to ARIA-E Incidence <\/p>\n
estimate pathological
volume, capture tau
heterogeneity, and detect
treatment response in
clinical trials <\/p>\n
7:30 a.m.-4:15 p.m.<\/p>\n
AIC ahead of AAIC*<\/p>\n
diffusion tensor imaging
endpoints using three
clinical trials in Alzheimer’s
disease <\/p>\n
in Alzheimer’s Disease
Through Lived Experience:
Implications For The Clinical
Dementia Rating Scale\u00a0 <\/p>\n
Topics: Drug Development<\/p>\n
Risk in Amyloid-Targeting
Therapies for Cognitively
Unimpaired Alzheimer’s
Disease
<\/p>\n
Topics: Dementia Care and
Psychosocial Factors\u00a0<\/p>\n
Healthcare Utilization and
Medicare Payments During
Cognitively Unimpaired
(Preclinical) Alzheimer’s
Disease Progression<\/p>\n
and Health Outcomes in
Those at Risk for Alzheimer’s
Disease Symptoms:
ANCHOR-AD Study Design<\/p>\n
rates among Medicare
beneficiaries with
Alzheimer’s disease or mild
cognitive impairment<\/p>\n
Elevated Plasma P-tau217
Status: A Cross-sectional
Analysis <\/p>\n
(NLP) Algorithms to Identify
Intracerebral Hemorrhage
>1 cm and Amyloid-Related
Imaging Abnormalities
(ARIA) in US Electronic
Medical Records<\/p>\n
By 2030, an estimated 78 million people worldwide are projected to have Alzheimer’s disease, rising from approximately 55 million today, from those living with the earliest changes associated with the disease, to those experiencing profound memory loss.\u00b9 The disease begins silently, often decades before any change in memory or thinking, with the accumulation of amyloid plaques in the brain,2 progressing through stages of increasing memory loss, behavioral changes, and growing dependence on caregivers.3
<\/p>\n
Kisunla is currently approved as an amyloid-targeting treatment for people with mild cognitive impairment as well as people with mild dementia stage of early symptomatic Alzheimer’s disease with confirmed amyloid pathology. Kisunla is a humanized monoclonal antibody that targets and reduces insoluble N-truncated pyroglutamate amyloid beta plaques, a defining feature of Alzheimer’s disease, and is administered as an intravenous infusion every four weeks. Kisunla can cause serious side effects, including ARIA and infusion-related reactions. Apolipoprotein E \u03b54 (ApoE \u03b54) homozygotes have a higher incidence of ARIA, including symptomatic and serious ARIA, and testing for ApoE \u03b54 status should be performed prior to initiating treatment. Carriers of one or two copies of the ApoE \u03b54 gene may be at higher risk of developing Alzheimer’s disease and experiencing ARIA. Patients should discuss any safety concerns with their healthcare providers.<\/p>\n
Kisunla\u00ae\u00a0(kih-SUHN-lah) is used to treat adults with early symptomatic Alzheimer’s disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease. \u00a0<\/p>\n
\n Dizziness\u00a0\u00a0
\n Nausea\u00a0
\n Difficulty
walking<\/p>\n
\n Vision changes
\n Seizures\u00a0<\/p>\n
\n About\u00a0all of\u00a0your medical conditions including if you are pregnant, breastfeeding, or plan to become pregnant or breastfeed. Kisunla has not been studied in people who were pregnant or breastfeeding. It is not known if Kisunla could harm your unborn or breastfeeding baby. \u00a0<\/p>\n
Kisunla is a prescription medicine given through an intravenous (IV) infusion using a needle inserted into a vein in your arm. Kisunla is given once every 4 weeks. Each infusion will last about 30 minutes.<\/p>\n
For more information about Kisunla, call 1-800-LillyRx (1-800-545-5979) or go to kisunla.lilly.com.\u00a0<\/p>\n
\n What is P-tau217 and how is it used in Alzheimer’s disease diagnosis?
\n How effective is Kisunla in slowing Alzheimer’s disease progression?
\n What was presented at the Alzheimer’s Association International Conference (AAIC) 2026?<\/p>\n
Lilly is a medicine company turning science into healing to make life better for people around the world. We’ve been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer’s disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit\u00a0Lilly.com<\/a> and\u00a0Lilly.com\/news<\/a>, or follow us on Facebook<\/a>, Instagram<\/a>, and LinkedIn<\/a>. P-LLY<\/p>\n
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the \u00ae and \u2122 symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company’s or their rights thereto. We do not intend the use or display of other companies’ trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.<\/p>\n
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about\u00a0Kisunla (donanemab-azbt) as a treatment for people with early symptomatic Alzheimer’s disease and as a potential treatment for patients with cognitively unimpaired Alzheimer’s disease and other conditions and reflects Lilly’s current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties\u00a0in the process of drug\u00a0research, development, and commercialization. Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with study results to date, that\u00a0Kisunla will receive additional regulatory approvals, or that Kisunla will be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly’s Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.\u00a0<\/p>\n
\n Sperling RA, Donohue MC, Rissman RA, et al. Amyloid and Tau Prediction of Cognitive and Functional Decline in Unimpaired Older Individuals: Longitudinal Data from the A4 and LEARN Studies.\u00a0J Prev Alzheimers Dis. 2024;11(4):802\u2013813.\u00a0\u00a0
\n Alzheimer’s Association. Stages of Alzheimer’s. www.alz.org\/alzheimers-dementia\/stages<\/a>.\u00a0\u00a0Accessed 24 June 2026.\u00a0
\n Alzheimer’s Association. 2025 Alzheimer’s disease\u00a0facts and figures.\u00a0Alzheimers\u00a0Dement. 2025;21(5):3708\u20133821.\u00a0<\/p>\n
\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 Michael Czapar; [email\u00a0protected]<\/a> (Investors)<\/p>\n![\"\"](\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=DE00398&Transmission_Id=202607091316PR_NEWS_USPR_____DE00398A&DateId=20260709\")
<\/p>\n